The Daptomycin Market is anticipated to grow at a robust CAGR of 4.4%. Therefore, the market value will further increase up to USD 5122.7 Million in the studied forecast period 2020-2027. Daptomycin is a lipopeptide antibiotic that naturally occurs in the body. It further kills bacteria by destroying the potential of their membrane. Therefore, it kills the bacteria as well as prevents their growth.
Various factors such as skin structure and complicated skin infections, and bloodstream infections, etc. are driving the market at a significant rate. According to the Daptomycin Market Analysis, the market will have significant growth of calcium-dependant antibiotics and bacterial metabolite will drive the market in this region.
The disease of COVID-19 disease had a drastic impact on the pharmaceutical and healthcare industry. Various manufacturers faced disruption due to lockdowns and fear of contamination. As a result, the manufacturing of necessary medications and treatment were heavily affected in the period 2020-2027. However, with the rapid development by key players and governments, the market is anticipated to regain its growth.
The increasing cases of complicated skin infections are a positive factor for the market. According to the report by World Health Organisation, around 900 million people were suffering from skin itching, changes in appearance, feel, and color. Also, the growing demand for Daptomycin to treat the increasing infection in the bloodstream will further drive the Daptomycin Market Growth.
However, lower use of Daptomycin to prevent the resistance to a new agent can prevent the market growth significantly. Also, the increasing cases of gram-positive bacteria can affect the market growth in the studied forecast period. Along with that, the increase in cases of right-sided infective endocarditis can also slow down the market growth.
Additionally, the role of Daptomycin as a bacterial metabolite and its usage as an antibacterial drug can open new opportunities for the market. Also, the investments and support by the key players and government for development and research will be beneficial for the market.
Furthermore, low awareness regarding effective medicine in various developing and poor countries can be a major challenge for the market growth. Also, the disruption in the supply chain caused by coronavirus can affect the Daptomycin Market significantly.
The Compound Annual Growth Rate (CAGR) of the Daptomycin Market is anticipated to grow at 4.4% substantially. It is further evaluated that the market value will also increase up to USD 5,122.7 Million in the studied forecast period. Favorable driers and market restraints will lead to substantial growth in the upcoming years.
Value Chain Analysis
The increasing demand for effective medicines and rising bacterial infections will further increase the Daptomycin Market Trends in the forthcoming years. Also, the support from various governments across the world and rapid market development will lead help to improve the value chain of the market.
The Daptomycin Market is divided into Age Group, Indication, and Strength. On the basis of age group, the market is segmented into Adult and Pediatric. The pediatric segment is considered to grow at the fastest rate in the forecast period. It is because Daptomycin is effectively tolerated as compared to the standard care given to children. Also, the adult segment will have the largest share in this segment. For adults, Daptomycin is used for treating adults suffering from Bacteraemia, as well as infective endocarditis.
Secondly, the indication segment is again divided into Bacteremia, Complicated Skin Structure Infections, and Others. According to the Daptomycin Market Analysis, the segment of complicated skin structure infection is expected to grow at the fastest rate. Along with that, it will hold the largest share in the studied forecast period.
However, bacteremia is a disease caused by a bacterial infection in the blood. It can be caused due to medical procedures and other activities. For this, antibiotics are required for the treatment otherwise they can cause sepsis due to delay. Along with that, the other sub-segment includes infections such as Superbug and Methicillin-Resistant Staphylococcus Aureus (MRDA).
On the basis of Strength, the market is again segmented into 500 mg and 350 mg. The 350 mg sub-segment is projected to grow at the fastest rate. Along with that, 500 mg will have the largest share in this segment in the forthcoming years.
On the basis of region, the Daptomycin Market Size is again divided into Europe, the Americas, Asia-Pacific, and Africa, and the Middle East. In the Americas, the Daptomycin is sold as Cubin by a company called Cubist Pharmaceuticals. However, the increasing cases of complicated skin structure infection and developments and research activities will improve the market growth.
Secondly, Europe is evaluated to hold the second-largest Daptomycin Market Share. It is mainly due to the approval for expanding market authorization for the Cubicin medicine. As a result, Europe will have significant growth in the forthcoming years.
Apart from that, the Asia-Pacific region is depicted to record the fastest growth in the upcoming years. The increasing development in the development of healthcare and pharmaceutical facilities and researches will drive the Daptomycin Market in the studied forecast period.
Lastly, Africa and the Middle East region are anticipated to grow at a steady rate. An increase in infection causing in bloodstreams and prevalence of sepsis among various countries will lead to a lucrative growth.
The Daptomycin Market is fragmented with the presence of various key players in the market. These key players [lay a crucial role in improving market growth. They do various acquisitions, collaborations, mergers, partnerships, new product launches to improve the market growth. Some of the crucial key players in this market are as follows.
No Recent Developments were found.
The report overview of the Daptomycin Market Outlook is listed below.
Report Score and Segmentation
The report score is to provide information about Daptomycin Market Forecast in the studied forecast period 2021-2028. The report highlights valuable information such as market drivers, challenges, recent development by key players, and many more. Apart from that, the information provided in this report is collected from various secondary and primary sources.
|Market Size||2027: USD 5,122.7 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Indication, Age Group and Strength|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co (US), Cipla (India), Pfizer (US), BE Pharmaceuticals (US), Dr. Reddy’s Laboratories (India), Mylan (US), Fresenius Kabi (Germany), Nichi-Iko Pharmaceutical (Japan), Novo Holdings A/S (Denmark), Zhejiang Hisun (China), Hengrui Medicine (China), Huadong Medicine (China), Civica Rx (US).|
|Key Market Opportunities||The rise in complicated skin and skin infections lead to increased demand for daptomycin.|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Daptomycin Market can thrive at 4.4% CAGR by 2027.
By 2027, the Daptomycin Market value can surpass USD 5,122.7 Million.
Fresenius Kabi, Novo Holdings A/Sare, and Nichi-Iko Pharmaceutical are some reputed Daptomycin Market players.
Surge in cases of blood infection can drive the Daptomycin Market.
Reluctance to used new drugs by physicians can hinder the Daptomycin Market rise.